Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway
8/27/2009 11:06:05 AM
More...
|
Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 (formerly DB-67) in Patients with Myelodysplastic Syndrome
7/23/2009 8:29:41 AM
More...
|
Arno Therapeutics Announces Three Poster Presentations at American Society of Clinical Oncology Annual Meeting
5/27/2009 9:31:14 AM
More...
|
FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
5/11/2009 8:54:57 AM
More...
|
Arno Therapeutics Reports 2008 Year-End Financial Results
3/31/2009 9:11:34 AM
More...
|
FDA Accepts IND for Arno Therapeutics' Pan-DAC / Akt Inhibitor, AR-42
3/17/2009 7:14:11 AM
More...
|
Arno Therapeutics Announces Third Quarter 2008 Financial Results
11/14/2008 8:19:28 AM
More...
|
Arno Therapeutics Appoints William F. Hamilton to Board of Directors
10/30/2008 8:34:22 AM
More...
|
Arno Therapeutics Announces Appointment of Roger G. Berlin, MD, as Chief Executive Officer and Director
9/3/2008 10:58:37 AM
More...
|
Arno Therapeutics Announces Second Quarter 2008 Financial Results
8/19/2008 10:35:43 AM
More...
|
|